Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide DNA methylation dynamics and RNA-seq analysis during grape (cv. 'Cabernet Franc') skin coloration.

Genomics·2024
Same author

Delivery Strategies for Colchicine as a Critical Dose Drug: Reducing Toxicity and Enhancing Efficacy.

Pharmaceutics·2024
Same author

Occult urothelial carcinoma with mediastinal metastasis: A case report.

Oncology letters·2024
Same author

Phase Identification and Discovery of an Elusive Polymorph of Drug-Polymer Inclusion Complex Using Automated 3D Electron Diffraction.

Angewandte Chemie (International ed. in English)·2024
Same author

Mediating and moderating effects of authoritative parenting styles on adolescent behavioral problems.

Frontiers in psychology·2024
Same author

A transformer-based diffusion probabilistic model for heart rate and blood pressure forecasting in Intensive Care Unit.

Computer methods and programs in biomedicine·2024

Related Experiment Video

Updated: Dec 26, 2025

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.0K

Programmed death-ligand 2 (PD-L2) expression in bladder cancer.

Yubo Yang1, Xiaoming Wang1, Yunjin Bai1

  • 1Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Urologic Oncology
|March 11, 2020
PubMed
Summary

High programmed death ligand-2 (PD-L2) expression is common in bladder cancer and associated with worse survival. This suggests PD-L2 may be a potential target for immune checkpoint blockade therapy.

Keywords:
Bladder cancerImmune checkpoint blockadeImmunotherapyPrognosisProgrammed death-ligand 2

More Related Videos

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
06:01

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Published on: October 6, 2022

1.7K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.6K

Related Experiment Videos

Last Updated: Dec 26, 2025

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.0K
Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
06:01

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Published on: October 6, 2022

1.7K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.6K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Immune checkpoint blockade is an effective therapy for bladder cancer.
  • Programmed death ligand-2 (PD-L2) plays a role in tumor immune evasion.

Purpose of the Study:

  • To investigate the expression of PD-L2 in bladder cancer patients.
  • To determine the association between PD-L2 expression and clinical outcomes.

Main Methods:

  • Immunohistochemistry was used to assess PD-L2 expression in 92 bladder cancer tissue samples.
  • Statistical analyses, including Kaplan-Meier and COX regression, were performed.

Main Results:

  • 73.9% of patients showed positive PD-L2 expression; 43.5% had moderate or strong expression.
  • High PD-L2 expression was linked to younger age (≤70 years) and smoking history.
  • High PD-L2 expression correlated with shorter overall survival and disease-free survival.

Conclusions:

  • Bladder cancer frequently exhibits high PD-L2 expression.
  • Elevated PD-L2 expression may predict a poorer prognosis.
  • PD-L2 represents a potential therapeutic target for immune checkpoint blockade in bladder cancer.